A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis

Bárbara R. Quinan, Alice Freitas Versiani, Flávio G. da Fonseca

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Dengue is no longer restricted to tropical developing countries, but is now a major global public health problem. Despite the recent license approval of the CYD-TDV vaccine in some countries, efforts to develop a more efficient vaccine against Dengue virus (DENV) continue. Herein, we evaluate the immunogenicity and level of protection of two potential vaccines against DENV based on recombinant modified vaccinia virus Ankara (rMVA). The vaccine addressing the Envelope protein from DENV serotype 3 to the endoplasmic reticulum elicited neutralizing antibodies titers which correlate with protection, and also confers protection upon challenge in a mouse model. Our results support the development of a tetravalent dengue vaccine with the further construction of rMVAs expressing proteins from the other DENV serotypes.

Original languageEnglish (US)
Pages (from-to)6120-6122
Number of pages3
JournalVaccine
Volume34
Issue number50
DOIs
StatePublished - Dec 7 2016
Externally publishedYes

Keywords

  • Dengue vaccine
  • Encephalitis model
  • MVA
  • Neutralizing antibodies
  • Recombinant MVA

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis'. Together they form a unique fingerprint.

Cite this